{"id":84810,"date":"2025-07-31T07:00:00","date_gmt":"2025-07-31T05:00:00","guid":{"rendered":"https:\/\/www.ipsen.com\/press-releases\/ipsen-publie-de-solides-resultats-au-premier-semestre-2025-et-releve-ses-objectifs-financiers-annuels-3124645\/"},"modified":"2025-08-04T11:05:24","modified_gmt":"2025-08-04T09:05:24","slug":"ipsen-publie-de-solides-resultats-au-premier-semestre-2025-et-releve-ses-objectifs-financiers-annuels-3124645","status":"publish","type":"press_release","link":"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-publie-de-solides-resultats-au-premier-semestre-2025-et-releve-ses-objectifs-financiers-annuels-3124645\/","title":{"rendered":"Ipsen publie de solides r\u00e9sultats au premier semestre 2025 et rel\u00e8ve ses objectifs financiers annuels"},"content":{"rendered":"<ul type=\"disc\">\n<li style=\"text-align: justify;\">Croissance des ventes totales du Groupe de 11,4% \u00e0 taux de change constant<sup>1<\/sup> ou 9,7% en donn\u00e9es publi\u00e9es, tir\u00e9e par les trois aires th\u00e9rapeutiques : 95,7% dans les Maladies Rares, 9,7% en Neurosciences et 6,4% en Oncologie<\/li>\n<li style=\"text-align: justify;\">R\u00e9sultat op\u00e9rationnel des activit\u00e9s de 656 millions d\u2019euros, en hausse de 21,9 % en donn\u00e9es publi\u00e9es, avec une marge op\u00e9rationnelle des activit\u00e9s repr\u00e9sentant 36,0% du chiffre d\u2019affaires, en progression de 3,6 points<\/li>\n<li style=\"text-align: justify;\">R\u00e9vision \u00e0 la hausse des objectifs financiers<sup>2<\/sup> 2025 : croissance du chiffre d\u2019affaires sup\u00e9rieure \u00e0 7,0% \u00e0 taux de change constant (objectif pr\u00e9c\u00e9dent\u00a0: sup\u00e9rieure \u00e0 5,0%) ; marge op\u00e9rationnelle des activit\u00e9s sup\u00e9rieure \u00e0 32,0% (objectif pr\u00e9c\u00e9dent : sup\u00e9rieure \u00e0 30,0%)<\/li>\n<li style=\"text-align: justify;\">Progr\u00e8s du portefeuille de R&amp;D incluant le d\u00e9p\u00f4t r\u00e9glementaire de tovorafenib en Europe et l\u2019initiation d\u2019un essai de Phase II de LANT<sup>3<\/sup> (IPN10200) dans la dystonie cervicale<\/li>\n<li style=\"text-align: justify;\">Approbation par la Commission europ\u00e9enne, le 23 juillet 2025, de Cabometyx<sup>\u00ae<\/sup> dans le traitement des tumeurs neuroendocrines (TNE) avanc\u00e9es, repr\u00e9sentant une sixi\u00e8me indication<\/li>\n<li style=\"text-align: justify;\">Prochaines \u00e9tapes cl\u00e9s avec les r\u00e9sultats de l\u2019essai pivot FALKON de fidrisertib dans la FOP<sup>4<\/sup> et les premi\u00e8res donn\u00e9es de preuve de concept de LANT en esth\u00e9tique<\/li>\n<\/ul>\n<p align=\"justify\"><strong>PARIS, FRANCE, 31 juillet 2025 &#8211;<\/strong> Ipsen (Euronext\u00a0: IPN\u00a0; ADR\u00a0: IPSEY), groupe biopharmaceutique mondial de sp\u00e9cialit\u00e9, pr\u00e9sente aujourd\u2019hui ses r\u00e9sultats financiers du premier semestre 2025.<\/p>\n<table style=\"border-collapse: collapse; margin-left: auto; margin-right: auto; width: 456.3pt;\">\n<tbody>\n<tr>\n<td style=\"width: 208px; text-align: center; vertical-align: middle;\" rowspan=\"2\"><strong>Extrait des \u00e9tats financiers consolid\u00e9s condens\u00e9s<\/strong><\/td>\n<td style=\"width: 101.87px; text-align: center; vertical-align: middle;\"><strong>S1 2025<\/strong><\/td>\n<td style=\"width: 107.4px; text-align: center; vertical-align: middle;\"><strong>S1 2024<\/strong><\/td>\n<td style=\"width: 191.14px; text-align: center; vertical-align: middle;\" colspan=\"2\"><strong>% de variation<\/strong><\/td>\n<\/tr>\n<tr>\n<td style=\"width: 101.87px; text-align: center; vertical-align: middle;\"><strong>m\u20ac<\/strong><\/td>\n<td style=\"width: 107.4px; text-align: center; vertical-align: middle;\"><strong>m\u20ac<\/strong><\/td>\n<td style=\"width: 107.47px; text-align: center; vertical-align: middle;\"><strong>R\u00e9alis\u00e9<\/strong><\/td>\n<td style=\"width: 83.67px; text-align: center; vertical-align: middle;\"><strong>TCC<\/strong><\/td>\n<\/tr>\n<tr>\n<td style=\"width: 208px; vertical-align: middle;\"><\/td>\n<td style=\"width: 101.87px; vertical-align: middle;\"><\/td>\n<td style=\"width: 107.4px; vertical-align: middle;\"><\/td>\n<td style=\"width: 107.47px; vertical-align: middle;\"><\/td>\n<td style=\"width: 83.67px; vertical-align: middle;\"><\/td>\n<\/tr>\n<tr>\n<td style=\"width: 208px; text-align: center; vertical-align: middle; border-bottom: solid black 1pt;\"><strong>Chiffre d&#8217;affaires<\/strong><\/td>\n<td style=\"width: 101.87px; text-align: center; vertical-align: middle; border-bottom: solid black 1pt;\"><strong>1\u00a0819,8<\/strong><\/td>\n<td style=\"width: 107.4px; text-align: center; vertical-align: middle; border-bottom: solid black 1pt;\"><strong>1\u00a0659,3<\/strong><\/td>\n<td style=\"width: 107.47px; text-align: center; vertical-align: middle; border-bottom: solid black 1pt;\"><strong>9,7 %<\/strong><\/td>\n<td style=\"width: 83.67px; text-align: center; vertical-align: middle; border-bottom: solid black 1pt;\"><strong>11,4 %<\/strong><\/td>\n<\/tr>\n<tr>\n<td style=\"width: 208px; text-align: center; vertical-align: middle; border-top: solid black 1pt;\"><strong>R\u00e9sultat op\u00e9rationnel des activit\u00e9s<\/strong><\/td>\n<td style=\"width: 101.87px; text-align: center; vertical-align: middle; border-top: solid black 1pt;\"><strong>655,8<\/strong><\/td>\n<td style=\"width: 107.4px; text-align: center; vertical-align: middle; border-top: solid black 1pt;\"><strong>538,0<\/strong><\/td>\n<td style=\"width: 107.47px; text-align: center; vertical-align: middle; border-top: solid black 1pt;\"><strong>21,9 %<\/strong><\/td>\n<td style=\"width: 83.67px; border-top: solid black 1pt; vertical-align: middle;\"><\/td>\n<\/tr>\n<tr>\n<td style=\"width: 208px; text-align: center; vertical-align: middle;\">Marge op\u00e9rationnelle des activit\u00e9s<\/td>\n<td style=\"width: 101.87px; text-align: center; vertical-align: middle;\">36,0 %<\/td>\n<td style=\"width: 107.4px; text-align: center; vertical-align: middle;\">32,4 %<\/td>\n<td style=\"width: 107.47px; text-align: center; vertical-align: middle;\">+3.6pts<\/td>\n<td style=\"width: 83.67px; vertical-align: middle;\"><\/td>\n<\/tr>\n<tr>\n<td style=\"width: 208px; text-align: center; vertical-align: middle;\"><strong>R\u00e9sultat net consolid\u00e9 des activit\u00e9s<\/strong><\/td>\n<td style=\"width: 101.87px; text-align: center; vertical-align: middle;\"><strong>508,3<\/strong><\/td>\n<td style=\"width: 107.4px; text-align: center; vertical-align: middle;\"><strong>399,4<\/strong><\/td>\n<td style=\"width: 107.47px; text-align: center; vertical-align: middle;\"><strong>27,3 %<\/strong><\/td>\n<td style=\"width: 83.67px; vertical-align: middle;\"><\/td>\n<\/tr>\n<tr>\n<td style=\"width: 208px; text-align: center; vertical-align: middle; border-bottom: solid black 1pt;\">B\u00e9n\u00e9fice dilu\u00e9 par action des activit\u00e9s<\/td>\n<td style=\"width: 101.87px; text-align: center; vertical-align: middle; border-bottom: solid black 1pt;\">6,07 \u20ac<\/td>\n<td style=\"width: 107.4px; text-align: center; vertical-align: middle; border-bottom: solid black 1pt;\">4,78 \u20ac<\/td>\n<td style=\"width: 107.47px; text-align: center; vertical-align: middle; border-bottom: solid black 1pt;\">27,0 %<\/td>\n<td style=\"width: 83.67px; border-bottom: solid black 1pt; vertical-align: middle;\"><\/td>\n<\/tr>\n<tr>\n<td style=\"width: 208px; text-align: center; vertical-align: middle;\"><strong>R\u00e9sultat op\u00e9rationnel IFRS<\/strong><\/td>\n<td style=\"width: 101.87px; text-align: center; vertical-align: middle;\"><strong>451,6<\/strong><\/td>\n<td style=\"width: 107.4px; text-align: center; vertical-align: middle;\"><strong>317,8<\/strong><\/td>\n<td style=\"width: 107.47px; text-align: center; vertical-align: middle;\"><strong>42,1 %<\/strong><\/td>\n<td style=\"width: 83.67px; vertical-align: middle;\"><\/td>\n<\/tr>\n<tr>\n<td style=\"width: 208px; text-align: center; vertical-align: middle;\">Marge op\u00e9rationnelle IFRS<\/td>\n<td style=\"width: 101.87px; text-align: center; vertical-align: middle;\">24,8 %<\/td>\n<td style=\"width: 107.4px; text-align: center; vertical-align: middle;\">19,2 %<\/td>\n<td style=\"width: 107.47px; text-align: center; vertical-align: middle;\">+5.7pts<\/td>\n<td style=\"width: 83.67px; vertical-align: middle;\"><\/td>\n<\/tr>\n<tr>\n<td style=\"width: 208px; text-align: center; vertical-align: middle;\"><strong>R\u00e9sultat net consolid\u00e9 IFRS<\/strong><\/td>\n<td style=\"width: 101.87px; text-align: center; vertical-align: middle;\"><strong>335,5<\/strong><\/td>\n<td style=\"width: 107.4px; text-align: center; vertical-align: middle;\"><strong>232,3<\/strong><\/td>\n<td style=\"width: 107.47px; text-align: center; vertical-align: middle;\"><strong>44,4 %<\/strong><\/td>\n<td style=\"width: 83.67px; vertical-align: middle;\"><\/td>\n<\/tr>\n<tr>\n<td style=\"width: 208px; text-align: center; vertical-align: middle; border-bottom: solid black 1pt;\">B\u00e9n\u00e9fice dilu\u00e9 par action IFRS<\/td>\n<td style=\"width: 101.87px; text-align: center; vertical-align: middle; border-bottom: solid black 1pt;\">4,00 \u20ac<\/td>\n<td style=\"width: 107.4px; text-align: center; vertical-align: middle; border-bottom: solid black 1pt;\">2,78 \u20ac<\/td>\n<td style=\"width: 107.47px; text-align: center; vertical-align: middle; border-bottom: solid black 1pt;\">44,0 %<\/td>\n<td style=\"width: 83.67px; border-bottom: solid black 1pt; vertical-align: middle;\"><\/td>\n<\/tr>\n<tr>\n<td style=\"width: 208px; text-align: center; vertical-align: middle;\"><strong>Cash-flow libre<\/strong><\/td>\n<td style=\"width: 101.87px; text-align: center; vertical-align: middle;\"><strong>483,2<\/strong><\/td>\n<td style=\"width: 107.4px; text-align: center; vertical-align: middle;\"><strong>393,5<\/strong><\/td>\n<td style=\"width: 107.47px; text-align: center; vertical-align: middle;\"><strong>22,8 %<\/strong><\/td>\n<td style=\"width: 83.67px; vertical-align: middle;\"><\/td>\n<\/tr>\n<tr>\n<td style=\"width: 208px; text-align: center; vertical-align: middle;\">Tr\u00e9sorerie \/ (Dette financi\u00e8re) nette<\/td>\n<td style=\"width: 101.87px; text-align: center; vertical-align: middle;\">487,6<\/td>\n<td style=\"width: 107.4px; text-align: center; vertical-align: middle;\">(6,8)<\/td>\n<td style=\"width: 107.47px; text-align: center; vertical-align: middle;\">n\/a<\/td>\n<td style=\"width: 83.67px; vertical-align: middle;\"><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p align=\"justify\">\u201cLes r\u00e9sultats du premier semestre refl\u00e8tent la dynamique soutenue du Groupe, avec une croissance dans nos trois aires th\u00e9rapeutiques, en particulier dans notre franchise des maladies rares du foie, qui se d\u00e9veloppe rapidement et progresse fortement \u00bb, d\u00e9clare David Loew, Directeur g\u00e9n\u00e9ral d\u2019Ipsen. \u00ab A la lumi\u00e8re de cette performance, je suis heureux de relever nos objectifs annuels de ventes et de rentabilit\u00e9. \u201c<\/p>\n<p align=\"justify\">\u201cJe me r\u00e9jouis \u00e9galement de constater la progression de notre portefeuille de R&amp;D et de nos produits, notamment avec l\u2019approbation r\u00e9cente du Cabometyx<sup>\u00ae<\/sup> dans les tumeurs neuroendocrines avanc\u00e9es par la Commission europ\u00e9enne, un domaine o\u00f9 Ipsen b\u00e9n\u00e9ficie d\u2019un solide h\u00e9ritage. Au second semestre, nous attendons la publication des r\u00e9sultats de notre \u00e9tude pivot de fidrisertib dans la fibrodysplasie ossifiante progressive et les premi\u00e8res donn\u00e9es de preuve de concept de notre neurotoxine \u00e0 action prolong\u00e9e en esth\u00e9tique. Notre strat\u00e9gie cibl\u00e9e, notre culture d\u2019excellence dans l\u2019ex\u00e9cution et notre engagement envers la science nous donnent les moyens d\u2019apporter des b\u00e9n\u00e9fices significatifs aux patients et \u00e0 la soci\u00e9t\u00e9.\u201d<\/p>\n<p><strong>Objectifs financiers pour l\u2019ann\u00e9e 2025<\/strong><\/p>\n<p align=\"justify\">Compte tenu de la forte performance du premier semestre, Ipsen revoit \u00e0 la hausse ses objectifs financiers pour 2025\u00a0:<\/p>\n<ul type=\"disc\">\n<li style=\"text-align: justify;\">Croissance des ventes totales sup\u00e9rieures \u00e0 7,0 % \u00e0 taux de change constant. Sur la base des taux de change moyens constat\u00e9s en juin 2025, Ipsen anticipe un impact d\u00e9favorable des devises de l\u2019ordre de 2%.<\/li>\n<li style=\"text-align: justify;\">Marge op\u00e9rationnelle des activit\u00e9s sup\u00e9rieure \u00e0 32,0 % du chiffre d\u2019affaires, int\u00e9grant des d\u00e9penses suppl\u00e9mentaires de R&amp;D li\u00e9es aux opportunit\u00e9s d\u2019innovation externe en phases pr\u00e9coce et interm\u00e9diaire<\/li>\n<\/ul>\n<p align=\"justify\">Ces perspectives anticipent un impact n\u00e9gatif sur les ventes de Somatuline en raison d\u2019une concurrence des g\u00e9n\u00e9riques potentiellement accrue aux \u00c9tats-Unis et en Europe. Elles excluent l\u2019impact de transactions potentielles de d\u00e9veloppement commercial en phase avanc\u00e9e (d\u00e9veloppement clinique de phase III ou au-del\u00e0).<\/p>\n<p><strong>Progr\u00e8s en 2025 du portefeuille de produits<\/strong><\/p>\n<p align=\"justify\">En mai 2025, Ipsen a pr\u00e9sent\u00e9 les donn\u00e9es d\u2019Iqirvo<sup>\u00ae<\/sup> (\u00e9lafibranor) issue de l\u2019\u00e9tude de Phase II ELMWOOD lors du congr\u00e8s de l\u2019European Association for the Study of the Liver. Cet essai a montr\u00e9 un profil de tol\u00e9rance favorable et une efficacit\u00e9 dose\u2011d\u00e9pendante sur 12 semaines chez des personnes atteintes de CSP<sup>5<\/sup>, une maladie h\u00e9patique rare d\u00e9pourvue d\u2019option th\u00e9rapeutique approuv\u00e9e.<\/p>\n<p align=\"justify\">En juin 2025, Ipsen a lanc\u00e9 une \u00e9tude de Phase II de LANT (IPN10200) dans la dystonie cervicale, marquant la quatri\u00e8me \u00e9tude du programme mondial de d\u00e9veloppement de cette neurotoxine de longue dur\u00e9e d\u2019action dans des indications th\u00e9rapeutiques et esth\u00e9tiques.<\/p>\n<p align=\"justify\">Le 23 juillet 2025, Ipsen a re\u00e7u l\u2019approbation de la Commission europ\u00e9enne pour Cabometyx<sup>\u00ae<\/sup> (cabozantinib) dans les tumeurs neuroendocrines avanc\u00e9es pr\u00e9alablement trait\u00e9es. Cette approbation repose sur les r\u00e9sultats positifs de l\u2019\u00e9tude de Phase III CABINET.<\/p>\n<p><strong>\u00c9tats financiers consolid\u00e9s<\/strong><\/p>\n<p align=\"justify\">Le conseil d\u2019administration a approuv\u00e9 les \u00e9tats financiers consolid\u00e9s le 30 juillet 2025. Les \u00e9tats financiers consolid\u00e9s condens\u00e9s du premier semestre 2025 ont \u00e9t\u00e9 soumis \u00e0 un examen limit\u00e9 des commissaires aux comptes du Groupe. Le rapport financier semestriel, en lien avec l\u2019information r\u00e9glement\u00e9e, sera disponible sur <a title=\"\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=RwzlhoOW2CV0CuBB3GqOZCXTijjxlMR_dIMId4fcCrRX06hIhIAPsHb03WVfw5otI4bLg4oGkYpwSIdmBa1-pg==\" target=\"_blank\" rel=\"nofollow noopener\"><u>ipsen.com<\/u><\/a> (section information r\u00e9glement\u00e9e).<\/p>\n<p><strong>Conference call<\/strong><\/p>\n<p align=\"justify\">Une conf\u00e9rence t\u00e9l\u00e9phonique et un webcast destin\u00e9s aux investisseurs et analystes se tiendront aujourd\u2019hui \u00e0 13h00, heure de Paris. Les participants peuvent acc\u00e9der \u00e0 la conf\u00e9rence et aux informations correspondantes <a title=\"\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=dqsKpICrlpBVxXdGT7hd1ABLaZpqm-RxuA38jqSKte8Cfqc8XbFYa-Mu2CoUFvkRZrMegLP8wBiTR1LsgkDW2vpqNlTrPNOxlDgm7AKrgu7n1jrvpD_kdUXPffHzV4w9VkFnCPaDB9HVu_CcGa_0ng0tjsu3aygnXpkQzzvgd4k=\" target=\"_blank\" rel=\"nofollow noopener\"><u>ici<\/u><\/a>. Pour en savoir plus sur le webcast, toutes les informations n\u00e9cessaires sont accessibles <a title=\"\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=dqsKpICrlpBVxXdGT7hd1B4oFCB7zStZLmAirpJlvmlEdsS8eWr9tCQNQYe0_-THz1Ak7rDtCF9o5ZWXqRDeLrb42Y-TnmwdyXnTiIqcuFI=\" target=\"_blank\" rel=\"nofollow noopener\"><u>ici<\/u><\/a>.<\/p>\n<p><strong>Calendrier<\/strong><\/p>\n<p align=\"justify\">Ipsen pr\u00e9voit de publier ses r\u00e9sultats du troisi\u00e8me trimestre le 22\u00a0octobre 2025.<\/p>\n<p><strong>Notes<\/strong><\/p>\n<p align=\"justify\">Tous les chiffres financiers sont exprim\u00e9s en millions d\u2019euros. Sauf indication contraire, les performances publi\u00e9es dans le pr\u00e9sent communiqu\u00e9 couvrent la p\u00e9riode de six mois courant jusqu\u2019au 30 juin 2025 (le premier semestre ou S1 2025) et la p\u00e9riode de trois mois jusqu\u2019au 30 juin 2025 (le deuxi\u00e8me trimestre ou T2 2025), comparativement \u00e0 la p\u00e9riode de six mois jusqu\u2019au 30 juin 2024 (S1 2024) et la p\u00e9riode de trois mois jusqu\u2019au 30 juin 2024 (T2 2024) respectivement. Les commentaires sont bas\u00e9s sur la performance du premier semestre 2025.<\/p>\n<table style=\"border-collapse: collapse; width: 480.75pt;\">\n<tbody>\n<tr>\n<td style=\"width: 641px; border-bottom: solid black 1pt; vertical-align: bottom;\"><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>A PROPOS D\u2019IPSEN<\/strong><\/p>\n<p align=\"justify\">Nous sommes un groupe biopharmaceutique mondial focalis\u00e9 sur la mise au point de m\u00e9dicaments innovants pour les patients dans trois domaines th\u00e9rapeutiques : l&#8217;Oncologie, les Maladies Rares et les Neurosciences.<\/p>\n<p align=\"justify\">Notre portefeuille de produits en R&amp;D s&#8217;appuie sur l&#8217;innovation interne et externe et sur pr\u00e8s de 100 ans d&#8217;exp\u00e9rience de d\u00e9veloppement au sein de hubs mondiaux aux \u00c9tats-Unis, en France et au Royaume- Uni. Nos \u00e9quipes, pr\u00e9sentes dans plus de 40 pays, et nos partenariats \u00e0 travers le monde nous permettent de proposer nos m\u00e9dicaments aux patients dans plus de 80 pays.<\/p>\n<p align=\"justify\">Ipsen est cot\u00e9 \u00e0 Paris (Euronext\u00a0: IPN) et aux \u00c9tats-Unis \u00e0 travers un programme d\u2019American Depositary Receipt (ADR\u00a0: IPSEY) sponsoris\u00e9 de niveau I. Pour plus d&#8217;informations, consultez <u>ipsen.com<\/u><u>.<\/u><\/p>\n<table style=\"border-collapse: collapse; width: 480.75pt;\">\n<tbody>\n<tr>\n<td style=\"width: 641px; border-bottom: solid black 1pt; vertical-align: bottom;\"><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>IPSEN CONTACTS<\/strong><\/p>\n<p><strong><em>Investisseurs<\/em><\/strong><\/p>\n<p><strong>Khalid Deojee \u00a0 <a title=\"khalid.deojee@ipsen.com\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=-kENFcGIXUlw59R0-UXBlRTN4UhUEcyhehL-xARgKd0-QnYh9S8V5lajN9-9PsBWZTzVXHCM0Iuy83ufpIR53o49XdlD9907nXxl2QzgygvGQpQeJS_cKB6fzToX6u6L\" target=\"_blank\" rel=\"nofollow noopener\">khalid.deojee@ipsen.com<\/a> \u00a0 +33 6 66 01 95 26<\/strong><\/p>\n<p><strong><em>Media<\/em><\/strong><\/p>\n<p><strong>Sally Bain \u00a0 <a title=\"sally.bain@ipsen.com\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=1kNXcQw5YEE3P-u_GH3AlShTCwZrR6f6YTvXG-JcPTwnPBH6qR-lNHgII8a1xMbV2tFSk0D3LSFet1y3V0amW4RnGFKHX-fV68_CMCMhXRg=\" target=\"_blank\" rel=\"nofollow noopener\">sally.bain@ipsen.com<\/a>\u00a0 \u00a0+1 857 32 00 517<\/strong><\/p>\n<p><strong>Anne Liontas \u00a0 <a title=\"anne.liontas@ipsen.com\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=Hf6Hnei2l2pncY8MFuKEBU1UaObZxzxe3RAsm7LF9q7VRZ1jz2X3-hXpVLdCOmcejh44HqHTEGsegnlZh2C3YB6ay-96j_FORLFDCPlPSiyK1QZRv2a60vonViTwVkCL\" target=\"_blank\" rel=\"nofollow noopener\">anne.liontas@ipsen.com<\/a>\u00a0 +33 7 67 34 72 96<\/strong><\/p>\n<hr \/>\n<p align=\"justify\"><sup>1<\/sup>\u00a0\u00a0\u00a0Variation \u00e0 taux de change constant, hors effets de change, \u00e9tabli en recalculant les performances de la p\u00e9riode consid\u00e9r\u00e9e sur la base des taux de change utilis\u00e9s pour la p\u00e9riode pr\u00e9c\u00e9dente<br \/>\n<sup>2<\/sup>\u00a0\u00a0\u00a0Excluant tout impact li\u00e9 \u00e0 d\u2019\u00e9ventuelles op\u00e9rations d\u2019innovation externe \u00e0 un stade avanc\u00e9 (d\u00e9veloppement clinique de Phase III ou ult\u00e9rieur)<br \/>\n<sup>3<\/sup>\u00a0\u00a0\u00a0Neurotoxines de longue dur\u00e9e d\u2019action ou LANT (\u00ab Long-Acting NeuroToxin \u00bb)<br \/>\n<sup>4<\/sup>\u00a0\u00a0\u00a0Fibrodysplasie ossifiante progressive<br \/>\n<sup>5<\/sup> Cholangite scl\u00e9rosante primitive<\/p>\n<p id=\"gnw_attachments_section-header\"><strong>Pi\u00e8ce jointe<\/strong><\/p>\n<ul id=\"gnw_attachments_section-items\">\n<li><a title=\"Ipsen - S1 2024 - Annonce des r\u00e9sultats\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=NtGU7hrbAotBX-_p2kR4r4CYWXqyK7AmypAnCDdzfsYDCy9SRx8cRRicO8CcXm0NklqUSwaOr4MBBX2QCRJ-GxID2lXuN-_7Tgt4ZKS_5EViW35gofgKdSLpmpgEi7sppqzy4-rQhWjDZmIg1nn_-Kf4tlriEdNPW4RqHdJIJyRA_0Z7K_a5I-CGC3IENmB13etbQhTti8UstjU9KHjGoQ==\" target=\"_blank\" rel=\"nofollow noopener\" data-wplink-edit=\"true\">Ipsen &#8211; S1 2025 &#8211; Annonce des r\u00e9sultats<\/a><\/li>\n<\/ul>\n<p><img decoding=\"async\" src=\"https:\/\/ml-eu.globenewswire.com\/media\/NWY4YzgyN2EtNmIyYi00ZTgzLWJmM2QtOGY1N2Q5ZmZlN2JlLTEyNjgxMTYtMjAyNS0wNy0zMS1mcg==\/tiny\/Ipsen-Pharma.png\" alt=\"\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"template":"","categories":[3556,3557],"tags":[],"class_list":["post-84810","press_release","type-press_release","status-publish","hentry","category-corporate-pressrelease-fr","category-financial-pressrelease-fr","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Ipsen publie de solides r\u00e9sultats au premier semestre 2025 et rel\u00e8ve ses objectifs financiers annuels<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-publie-de-solides-resultats-au-premier-semestre-2025-et-releve-ses-objectifs-financiers-annuels-3124645\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ipsen publie de solides r\u00e9sultats au premier semestre 2025 et rel\u00e8ve ses objectifs financiers annuels\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-publie-de-solides-resultats-au-premier-semestre-2025-et-releve-ses-objectifs-financiers-annuels-3124645\/\" \/>\n<meta property=\"og:site_name\" content=\"Global\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-04T09:05:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ml-eu.globenewswire.com\/media\/NWY4YzgyN2EtNmIyYi00ZTgzLWJmM2QtOGY1N2Q5ZmZlN2JlLTEyNjgxMTYtMjAyNS0wNy0zMS1mcg==\/tiny\/Ipsen-Pharma.png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@ipsengroup\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-publie-de-solides-resultats-au-premier-semestre-2025-et-releve-ses-objectifs-financiers-annuels-3124645\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-publie-de-solides-resultats-au-premier-semestre-2025-et-releve-ses-objectifs-financiers-annuels-3124645\/\"},\"author\":{\"name\":\"IPSEN\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/05e5e9dcc9e44c61de10732d1d0a1352\"},\"headline\":\"Ipsen publie de solides r\u00e9sultats au premier semestre 2025 et rel\u00e8ve ses objectifs financiers annuels\",\"datePublished\":\"2025-07-31T05:00:00+00:00\",\"dateModified\":\"2025-08-04T09:05:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-publie-de-solides-resultats-au-premier-semestre-2025-et-releve-ses-objectifs-financiers-annuels-3124645\/\"},\"wordCount\":1296,\"publisher\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-publie-de-solides-resultats-au-premier-semestre-2025-et-releve-ses-objectifs-financiers-annuels-3124645\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ml-eu.globenewswire.com\/media\/NWY4YzgyN2EtNmIyYi00ZTgzLWJmM2QtOGY1N2Q5ZmZlN2JlLTEyNjgxMTYtMjAyNS0wNy0zMS1mcg==\/tiny\/Ipsen-Pharma.png\",\"articleSection\":[\"Corporate\",\"Financier\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-publie-de-solides-resultats-au-premier-semestre-2025-et-releve-ses-objectifs-financiers-annuels-3124645\/\",\"url\":\"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-publie-de-solides-resultats-au-premier-semestre-2025-et-releve-ses-objectifs-financiers-annuels-3124645\/\",\"name\":\"Ipsen publie de solides r\u00e9sultats au premier semestre 2025 et rel\u00e8ve ses objectifs financiers annuels\",\"isPartOf\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-publie-de-solides-resultats-au-premier-semestre-2025-et-releve-ses-objectifs-financiers-annuels-3124645\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-publie-de-solides-resultats-au-premier-semestre-2025-et-releve-ses-objectifs-financiers-annuels-3124645\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ml-eu.globenewswire.com\/media\/NWY4YzgyN2EtNmIyYi00ZTgzLWJmM2QtOGY1N2Q5ZmZlN2JlLTEyNjgxMTYtMjAyNS0wNy0zMS1mcg==\/tiny\/Ipsen-Pharma.png\",\"datePublished\":\"2025-07-31T05:00:00+00:00\",\"dateModified\":\"2025-08-04T09:05:24+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-publie-de-solides-resultats-au-premier-semestre-2025-et-releve-ses-objectifs-financiers-annuels-3124645\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-publie-de-solides-resultats-au-premier-semestre-2025-et-releve-ses-objectifs-financiers-annuels-3124645\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-publie-de-solides-resultats-au-premier-semestre-2025-et-releve-ses-objectifs-financiers-annuels-3124645\/#primaryimage\",\"url\":\"https:\/\/ml-eu.globenewswire.com\/media\/NWY4YzgyN2EtNmIyYi00ZTgzLWJmM2QtOGY1N2Q5ZmZlN2JlLTEyNjgxMTYtMjAyNS0wNy0zMS1mcg==\/tiny\/Ipsen-Pharma.png\",\"contentUrl\":\"https:\/\/ml-eu.globenewswire.com\/media\/NWY4YzgyN2EtNmIyYi00ZTgzLWJmM2QtOGY1N2Q5ZmZlN2JlLTEyNjgxMTYtMjAyNS0wNy0zMS1mcg==\/tiny\/Ipsen-Pharma.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-publie-de-solides-resultats-au-premier-semestre-2025-et-releve-ses-objectifs-financiers-annuels-3124645\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.ipsen.com\/fr\/home\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ipsen publie de solides r\u00e9sultats au premier semestre 2025 et rel\u00e8ve ses objectifs financiers annuels\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#website\",\"url\":\"https:\/\/www.ipsen.com\/fr\/\",\"name\":\"Global\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.ipsen.com\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#organization\",\"name\":\"IPSEN\",\"url\":\"https:\/\/www.ipsen.com\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.ipsen.com\/wp-content\/uploads\/2023\/12\/Latest_Ipsen-logo_168x48.svg\",\"contentUrl\":\"https:\/\/www.ipsen.com\/wp-content\/uploads\/2023\/12\/Latest_Ipsen-logo_168x48.svg\",\"caption\":\"IPSEN\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/Ipsengroup\",\"https:\/\/x.com\/ipsengroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/05e5e9dcc9e44c61de10732d1d0a1352\",\"name\":\"IPSEN\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/b569564123e1c5c4bb45b008fc273d5bfdd6464d8a8497307ebbe91af50ed000?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/b569564123e1c5c4bb45b008fc273d5bfdd6464d8a8497307ebbe91af50ed000?s=96&d=mm&r=g\",\"caption\":\"IPSEN\"},\"sameAs\":[\"https:\/\/www.ipsen.com\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ipsen publie de solides r\u00e9sultats au premier semestre 2025 et rel\u00e8ve ses objectifs financiers annuels","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-publie-de-solides-resultats-au-premier-semestre-2025-et-releve-ses-objectifs-financiers-annuels-3124645\/","og_locale":"fr_FR","og_type":"article","og_title":"Ipsen publie de solides r\u00e9sultats au premier semestre 2025 et rel\u00e8ve ses objectifs financiers annuels","og_url":"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-publie-de-solides-resultats-au-premier-semestre-2025-et-releve-ses-objectifs-financiers-annuels-3124645\/","og_site_name":"Global","article_modified_time":"2025-08-04T09:05:24+00:00","og_image":[{"url":"https:\/\/ml-eu.globenewswire.com\/media\/NWY4YzgyN2EtNmIyYi00ZTgzLWJmM2QtOGY1N2Q5ZmZlN2JlLTEyNjgxMTYtMjAyNS0wNy0zMS1mcg==\/tiny\/Ipsen-Pharma.png","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_site":"@ipsengroup","twitter_misc":{"Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-publie-de-solides-resultats-au-premier-semestre-2025-et-releve-ses-objectifs-financiers-annuels-3124645\/#article","isPartOf":{"@id":"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-publie-de-solides-resultats-au-premier-semestre-2025-et-releve-ses-objectifs-financiers-annuels-3124645\/"},"author":{"name":"IPSEN","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/05e5e9dcc9e44c61de10732d1d0a1352"},"headline":"Ipsen publie de solides r\u00e9sultats au premier semestre 2025 et rel\u00e8ve ses objectifs financiers annuels","datePublished":"2025-07-31T05:00:00+00:00","dateModified":"2025-08-04T09:05:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-publie-de-solides-resultats-au-premier-semestre-2025-et-releve-ses-objectifs-financiers-annuels-3124645\/"},"wordCount":1296,"publisher":{"@id":"https:\/\/www.ipsen.com\/fr\/#organization"},"image":{"@id":"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-publie-de-solides-resultats-au-premier-semestre-2025-et-releve-ses-objectifs-financiers-annuels-3124645\/#primaryimage"},"thumbnailUrl":"https:\/\/ml-eu.globenewswire.com\/media\/NWY4YzgyN2EtNmIyYi00ZTgzLWJmM2QtOGY1N2Q5ZmZlN2JlLTEyNjgxMTYtMjAyNS0wNy0zMS1mcg==\/tiny\/Ipsen-Pharma.png","articleSection":["Corporate","Financier"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-publie-de-solides-resultats-au-premier-semestre-2025-et-releve-ses-objectifs-financiers-annuels-3124645\/","url":"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-publie-de-solides-resultats-au-premier-semestre-2025-et-releve-ses-objectifs-financiers-annuels-3124645\/","name":"Ipsen publie de solides r\u00e9sultats au premier semestre 2025 et rel\u00e8ve ses objectifs financiers annuels","isPartOf":{"@id":"https:\/\/www.ipsen.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-publie-de-solides-resultats-au-premier-semestre-2025-et-releve-ses-objectifs-financiers-annuels-3124645\/#primaryimage"},"image":{"@id":"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-publie-de-solides-resultats-au-premier-semestre-2025-et-releve-ses-objectifs-financiers-annuels-3124645\/#primaryimage"},"thumbnailUrl":"https:\/\/ml-eu.globenewswire.com\/media\/NWY4YzgyN2EtNmIyYi00ZTgzLWJmM2QtOGY1N2Q5ZmZlN2JlLTEyNjgxMTYtMjAyNS0wNy0zMS1mcg==\/tiny\/Ipsen-Pharma.png","datePublished":"2025-07-31T05:00:00+00:00","dateModified":"2025-08-04T09:05:24+00:00","breadcrumb":{"@id":"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-publie-de-solides-resultats-au-premier-semestre-2025-et-releve-ses-objectifs-financiers-annuels-3124645\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-publie-de-solides-resultats-au-premier-semestre-2025-et-releve-ses-objectifs-financiers-annuels-3124645\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-publie-de-solides-resultats-au-premier-semestre-2025-et-releve-ses-objectifs-financiers-annuels-3124645\/#primaryimage","url":"https:\/\/ml-eu.globenewswire.com\/media\/NWY4YzgyN2EtNmIyYi00ZTgzLWJmM2QtOGY1N2Q5ZmZlN2JlLTEyNjgxMTYtMjAyNS0wNy0zMS1mcg==\/tiny\/Ipsen-Pharma.png","contentUrl":"https:\/\/ml-eu.globenewswire.com\/media\/NWY4YzgyN2EtNmIyYi00ZTgzLWJmM2QtOGY1N2Q5ZmZlN2JlLTEyNjgxMTYtMjAyNS0wNy0zMS1mcg==\/tiny\/Ipsen-Pharma.png"},{"@type":"BreadcrumbList","@id":"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-publie-de-solides-resultats-au-premier-semestre-2025-et-releve-ses-objectifs-financiers-annuels-3124645\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ipsen.com\/fr\/home\/"},{"@type":"ListItem","position":2,"name":"Ipsen publie de solides r\u00e9sultats au premier semestre 2025 et rel\u00e8ve ses objectifs financiers annuels"}]},{"@type":"WebSite","@id":"https:\/\/www.ipsen.com\/fr\/#website","url":"https:\/\/www.ipsen.com\/fr\/","name":"Global","description":"","publisher":{"@id":"https:\/\/www.ipsen.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ipsen.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.ipsen.com\/fr\/#organization","name":"IPSEN","url":"https:\/\/www.ipsen.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ipsen.com\/wp-content\/uploads\/2023\/12\/Latest_Ipsen-logo_168x48.svg","contentUrl":"https:\/\/www.ipsen.com\/wp-content\/uploads\/2023\/12\/Latest_Ipsen-logo_168x48.svg","caption":"IPSEN"},"image":{"@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/Ipsengroup","https:\/\/x.com\/ipsengroup"]},{"@type":"Person","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/05e5e9dcc9e44c61de10732d1d0a1352","name":"IPSEN","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/b569564123e1c5c4bb45b008fc273d5bfdd6464d8a8497307ebbe91af50ed000?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b569564123e1c5c4bb45b008fc273d5bfdd6464d8a8497307ebbe91af50ed000?s=96&d=mm&r=g","caption":"IPSEN"},"sameAs":["https:\/\/www.ipsen.com"]}]}},"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/press_release\/84810","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/press_release"}],"about":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/types\/press_release"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"version-history":[{"count":2,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/press_release\/84810\/revisions"}],"predecessor-version":[{"id":84835,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/press_release\/84810\/revisions\/84835"}],"wp:attachment":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/media?parent=84810"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/categories?post=84810"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/tags?post=84810"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}